Billionaire Ken Fisher’s Healthcare Picks for Q3 Include Pfizer Inc. (PFE)

Fisher and his team kept their stake in Novo Nordisk A/S (ADR) (NYSE:NVO), a provider of diabetes drugs and other pharmaceuticals, about constant between April and June at 2.7 million shares. Markets are pricing Novo Nordisk for future growth with trailing and forward earnings multiples of 23 and 20 respectively. Going by recent reports there has in fact been some improvement in the company’s financials: in its last quarterly report revenue rose 13% compared to the first quarter of 2012, and with margins expanding as well net income growth came in at 28%.

As such Novo Nordisk might be worth taking a look at for investors with enough knowledge of healthcare to evaluate whether or not it has enough growth potential to continue its strong performance over the next several years. In value terms Pfizer Inc. (NYSE:PFE) does seem somewhat interesting as well, though it might be better to wait for further results to see if management can in fact improve the company’s efficiency enough to improve profits even given the stability of its business.

Disclosure: I own no shares of any stocks mentioned in this article.